TBI Phase-Targeted Therapy
EPO derivatives including ARA290 reviewed for traumatic brain injury, with signaling biased toward PI3K-AKT and away from JAK2-STAT5.
[1]An 11-amino-acid synthetic peptide derived from the B-helix of erythropoietin (EPO), engineered to retain tissue-protective and anti-inflammatory effects without erythropoietic activity. Selective activation of the innate repair receptor (IRR) on stressed and injured tissue.
At a glance
- Type
- 11-amino-acid synthetic peptide derived from the B-helix of erythropoietin (EPO)
- Target
- Innate repair receptor (EPOR-CD131) on stressed or injured tissue
- Route
- Subcutaneous
- Hematologic activity
- No clinically relevant increase in hemoglobin or hematocrit
- Regulatory
- Not FDA approved; available via compounding pharmacies for research use only
What the research supports
ARA290 is the cleanest example of a peptide engineered to separate tissue protection from a known liability. The strongest human data is in diabetic neuropathy.
Periapical Inflammation
ARA290 attenuated apical periodontitis via SIRT1/NF-kB/IL-1 beta pathway modulation, confirming broad anti-inflammatory reach.
[2]Pegmolesatide EPOR-CD131
Related work confirmed EPOR-CD131-dependent JAK2/STAT3 signaling pathway in cardiomyocyte hypertrophy modulation.
[3]Diabetic Neuropathy Phase 2
Improvement in corneal nerve fiber density and pain scores in Phase 2 trials; the strongest human evidence in the ARA290 literature.
[4]Summary of key findings
Receptor-Selective Design
Targets innate repair receptor (EPOR-CD131) only on stressed or injured tissue; healthy tissue is spared from activation.
No Hematologic Activity
No clinically relevant increase in hemoglobin or hematocrit, the key advantage over native EPO.
Diabetic Neuropathy Indication
Phase 2 trials demonstrated objective corneal nerve fiber density improvement and subjective pain reduction.
Exceptional Safety Profile
Multiple completed trials show no significant hematologic, thrombotic, or organ toxicity signals.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Subcutaneous Protocol
- 4 mg daily for 28 days, AM or PM on an empty stomach (standard protocol).
- Alternative Schedule
- 4 mg three times weekly per some research protocols.
- Cycling
- Typical research cycles run 4 to 12 weeks; insufficient data for indefinite continuous dosing.
- Stacking
- Pairs with BPC-157 for tissue repair and with low-dose naltrexone for chronic inflammatory states.
Protocol reference
| Compound | Dose | Timing | Frequency | Duration |
|---|---|---|---|---|
| ARA-290 | 4 mg | AM or PM empty stomach | Daily | 28 days |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
Cibinetide is the cleanest example of a peptide engineered specifically to separate tissue protection from a known liability. EPO repairs tissue but raises clot risk; ARA290 retains the repair signaling without the hematologic activity. The mechanism is receptor-selective: it targets the innate repair receptor that only appears on stressed or injured tissue, which is why it is well tolerated in healthy tissue.
The strongest human data is in diabetic neuropathy, where it improved both objective small fiber nerve density and subjective pain scores. Safety is exceptional for a peptide of this class. Position it as investigational, with the strongest case in neuropathic and inflammatory pain contexts where conventional options have failed. Pairs well in protocols with BPC-157 for tissue repair or with low-dose naltrexone for chronic inflammatory states.
Diabetic Neuropathy
Phase 2 evidence for corneal nerve density and pain score improvement.
Anti-Inflammatory Repair
Innate repair receptor activation without erythropoietic effects.
Exceptional Safety
No hematologic, thrombotic, or organ toxicity signals across completed trials.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Sun et al., 2026 Phase-targeted EPO derivatives for traumatic brain injury
- 2Wang et al., 2025 ARA290 attenuates apical periodontitis via SIRT1/NF-kB
- 3Zhang et al., 2025 Pegmolesatide: EPOR-CD131-dependent signaling in cardiomyocyte hypertrophy
- 4Brines et al., 2015 Cibinetide Phase 2 diabetic neuropathy trial: corneal nerve fiber density and pain score outcomes
Regulatory status, cautions and contraindications
Regulatory Status
ARA-290 is not FDA approved. Available via compounding pharmacies for research use only.
Theoretical Caution
Active malignancy: theoretical caution due to pro-survival signaling. Use only under licensed provider supervision.
Pregnancy and Lactation
Insufficient data available. Avoid use during pregnancy and lactation until further evidence is established.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.